Anti-viral drugs
[용어속성] Drug
The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections
Immunology
[키워드] 2019-nCoV
Anti-viral drugs
clinical disease
clinical feature
Comparative
coronavirus
COVID-19
Cytokine storm
disease
dysfunction
Evidence
exhibit
homologous
immunological characteristics
immunology
Immunopathogenesis
immunopathology
Immunotherapy
Infection
knowledge
mechanism
MERS
MERS-CoV
Novel coronavirus
pandemic
Pathogenesis
pathogenesis of COVID-19
pathogenicity
patients
recent finding
Research
responsible
SARS-CoV
SARS-CoV-2
Stage
the disease
therapeutic strategy
Transmissibility
Vaccines
virus
[DOI] 10.3389/fimmu.2020.02033 PMC 바로가기 [Article Type] Immunology
[DOI] 10.3389/fimmu.2020.02033 PMC 바로가기 [Article Type] Immunology
Insights Into Dynamics of Inhibitor and Ubiquitin-Like Protein Binding in SARS-CoV-2 Papain-Like Protease
Molecular Biosciences
[키워드] Alter
Anti-viral drugs
assays
binding
binding affinity
binding modes
binding site
Biophysics
caused
Chemotherapy
comparison
Compound
compounds
computational biology and chemistry
conformational change
coronavirus
Coronaviruses
drug
drug design
Dynamics
effective inhibitor
exhibited
immune response
IMPROVE
in viral
inhibiting
inhibitor
innate immune response
insight
Interaction
involved
Ligand
MERS-CoV
molecular
molecular docking
naphthalene
non-covalent molecular recognition
Older
PLPro
protease
Protein
protein entropy
protein inhibition
protein-protein interaction
remained
Replication
residue
SARS-CoV-1
SARS-CoV-2
similarity
Structure-based drug design
suggested
the binding affinity
Vaccine
virus
[DOI] 10.3389/fmolb.2020.00174 PMC 바로가기 [Article Type] Molecular Biosciences
[DOI] 10.3389/fmolb.2020.00174 PMC 바로가기 [Article Type] Molecular Biosciences
Prospects for RNAi Therapy of COVID-19
Bioengineering and Biotechnology
[키워드] acute respiratory disease
Analysis
Anti-viral drugs
approach
approaches
approved
authors
binding
caused
clinical setting
Consequences
COVID-19
develop
drug delivery
drug treatment
duplication
effective
effective intervention
emerging disease
Factor
faster
feasibility
Host
host response
immune system
Infection
limitation
lung
lung failure
lung tissue
mechanism
modulating
molecular
nucleic acid
pandemic
Perspective
pulmonary system
Region
Respiratory function
resulting
RNA
RNA interference
SARS-CoV
SARS-CoV-2
siRNA
target
targets
the SARS-CoV-2
the SARS-CoV-2 virus
Therapeutic approach
therapeutic target
Therapies
therapy
translate
urgency
Vaccine
viral entry
viral genome
viral spread
virus
[DOI] 10.3389/fbioe.2020.00916 PMC 바로가기 [Article Type] Bioengineering and Biotechnology
[DOI] 10.3389/fbioe.2020.00916 PMC 바로가기 [Article Type] Bioengineering and Biotechnology
Profiles of COVID-19 clinical trials in the Chinese Clinical Trial Registry
Review
[키워드] adopted
anti-viral drug
Anti-viral drugs
caused
Characteristics
Chinese
clinical
clinical study
clinical trial
clinical trials
comprehensive analysis
COVID-19
COVID-19 pandemic
COVID19
Effect
effective drug
effort
global public health
Government
help
identify
International
Intervention
outcome
profile
public health
Registered
registry
resource
significantly
supported
Traditional Chinese medicine
Vaccine
virus
[DOI] 10.1080/22221751.2020.1791736 PMC 바로가기 [Article Type] Review
[DOI] 10.1080/22221751.2020.1791736 PMC 바로가기 [Article Type] Review
An updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic
Article
[키워드] 5’-UTR, 5′-untranslated region
ACE-2, Angiotensin-converting enzyme 2
ANG-I, angiotensin I
Ang-II, Angiotensin II
Anti-viral drugs
ARI, acute renal injury
convalescent plasma
COVID-19
CRI, chronic renal injury
CTD, C-terminal domain
CVD, cardiovascular diseases
ergic, endoplasmic reticulum-golgi intermediate compartment
MERS-CoV, Middle East respiratory syndrome coronavirus
NTD, N-terminal domain
RBD, receptor-binding domain
SARS-CoV-2
SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2
SARS-CoV, severe acute respiratory syndrome coronavirus
TMPRSS, transmembrane protease serine protease-2 (TMPRSS-2)
Vaccines
[DOI] 10.1016/j.lfs.2020.118105 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.lfs.2020.118105 PMC 바로가기 [Article Type] Article
COVID-19 PICU guidelines: for high- and limited-resource settings
Special Article
[키워드] adjuvant therapies
Adults
affected
Anti-inflammatory
anti-thrombotic therapy
Anti-viral drugs
Cardiopulmonary
Care
children
children with COVID-19
clinical manifestation
co-morbidity
COVID-19
COVID-19 pandemic
COVID-19 patient
Critical
Critically ill
decrease
described
develop
disease
distress
ECMO
Evidence
explain
ICU
Impact
infected with SARS-CoV-2
Inflammatory
intensive care
International
MIS-C
morbidity
Mortality
Patient
pediatric
presenting
receive
recommendation
Referring
Region
replaced
Result
SARS-COV-2 infection
Sepsis
Septic shock
syndrome
[DOI] 10.1038/s41390-020-1053-9 PMC 바로가기 [Article Type] Special Article
[DOI] 10.1038/s41390-020-1053-9 PMC 바로가기 [Article Type] Special Article
Clinical observation and management of COVID-19 patients
Commentary
[키워드] abnormality
addition
Anti-viral drugs
anticoagulation
antiviral drugs
approach
Care
Characteristics
China
Chinese
clinical
Clinical course
Clinical management
clinical trial
coagulation function
coronavirus
COVID-19 cases
COVID-19 patient
COVID-19 patients
critically ill patients
develop
expresse
Infectious disease
Intervention
Intravenous immunoglobulin
low molecular weight
management
Multiorgan
observation
observé
Patient
Professor
responsible
SARS
SARS-CoV-2
SARS-COV-2 infection
Shanghai
Supportive treatment
therapy
Treatment
Trial
unique
Wuhan
[DOI] 10.1080/22221751.2020.1741327 PMC 바로가기 [Article Type] Commentary
[DOI] 10.1080/22221751.2020.1741327 PMC 바로가기 [Article Type] Commentary
Sambucus nigra extracts inhibit infectious bronchitis virus at an early point during replication
Research Article
[키워드] Rhodiola rosea
Sambucus nigra
Anti-viral drugs
bronchitis
Cell
compounds
Concentration
coronavirus
Cytopathic effect
cytotoxicity
derivative
determined
different
Effect
electron microscopy
highest
IBV
infected cell
Infection
Infectious Bronchitis Virus
inhibit
magnitude
mechanism of action
membrane
MOI
multiplicity of infection
Nigella Sativa
non-infectious
other coronavirus
pathogenic
plant
Plaque assay
Prevent
protocol
quantified
reduced
Replication
Result
Rhodiola
Safe
Sambucus
solvent
staining
suggested
supernatant
tested
tissue
transmission electron microscopy
treat
treated
Treatment
trypan blue staining
vaccination
Vero Cell
vesicles
viral titer
virion
virus
virus inhibition
virus titer
viruses
[DOI] 10.1186/1746-6148-10-24 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1186/1746-6148-10-24 PMC 바로가기 [Article Type] Research Article
Structure and Inhibition of the SARS Coronavirus Envelope Protein Ion Channel
Research Article
[키워드] 2003
acute respiratory syndrome
affecting
alteration
Anti-viral drugs
antiviral strategy
Author
binding site
C-terminal
Cell
channel
characterized
common cold
coronavirus
coronavirus protein
described
determined
distribution
drug design
E protein
embryonic kidney
envelope
envelope protein
event
expressed
expressing
feature
form
found
full length
HEK-293
Human
humans
in vitro
inactivation
infect
inhibited
inhibition
Ion
lethal disease
mammalian cell
mammals
membrane
Mild
morphology
N-terminal
NMR
pandemic
Pathogenesis
pharmacological target
platform
produced
Protein
Proteins
provide
reduced
reported
responsible
SARS-CoV
SARS-CoV E
shown
significantly
Structure
supported
transmembrane domain
Validity
variety
viral envelope
viral pathogen
viral replication
virion
virus
viruses
[DOI] 10.1371/journal.ppat.1000511 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1371/journal.ppat.1000511 PMC 바로가기 [Article Type] Research Article